reports
- ABGSC Healthcare Research
- Sten Gustafsson
Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference...
Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference call on 19 August 2025 at 11.00am CEST Tuesday, 19 August 2025 at 11.00 - 12.00h CESTIn connection with the publication of Coloplast’s interim financial results for 9M 2024/25, to be released same day in the morning around 07.30h CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available d...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Sten Gustafsson
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Sten Gustafsson
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Sten Gustafsson
- ABGSC Healthcare Research
- Philip Ekengren
- Sten Gustafsson
- ABGSC Healthcare Research
- Philip Ekengren
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- Maria Vara
BONESUPPORT: 2025 Trim; Spine optionality kicks in
Following Q2 earnings, we revisited our expectations across all business segments, leading to a 9% 2025E sales cut, majorly driven by FX headwinds on US sales, while country-specific policies in EUROW led to softer-than-expected H1 growth. Our long-term thesis remains unchanged, and we see improvin
- ABGSC Healthcare Research
- Sten Gustafsson
- Maria Vara
BONESUPPORT: Q2 US momentum in line; softer EU and FX weigh on EBIT
BONESUPPORT reported Q2 2025 net sales of SEK 284.4m, slightly below CSS SEK 291m (Stifel est. SEK 299m), with the deviation primarily due to a softer-than-expected European performance. Growth was led by the US, which grew 36% YoY reported (49% CER), though it fell -2%, and -4% vs CSS and our expe
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Philip Ekengren
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
Elekta AB: 1 director
A director at Elekta AB bought 113,633 shares at 48.343SEK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- ABGSC Healthcare Research
- Sten Gustafsson
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.